ReviewMolecular therapy. Nucleic acids2017
Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine.
Review in Molecular therapy. Nucleic acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 64 citations in OpenAlex.
- Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).Neuro-oncology · 2022Trial
- Diagnostic Accuracy of Dermoscopy for Spitzoid Tumours in Adults.Acta dermato-venereologica · 2026Article
- Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?Pharmaceuticals (Basel, Switzerland) · 2024Review
- The evolutionary impact of childhood cancer on the human gene pool.Nature communications · 2024Article
- Implementing data on targeted therapy from the INFORM registry platform for children with relapsed cancer in Sweden.Frontiers in oncology · 2024Article
- Article
- RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming.Current treatment options in oncology · 2023Review
- The Role of Phase-Separated Condensates in Fusion Oncoprotein-Driven Cancers.Annual review of cancer biology · 2023Article
- Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.International journal of molecular sciences · 2023Review
- Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Pediatric precision oncology: "better three hours too soon than a minute too late".Frontiers in oncology · 2023Article
- Fusion InPipe, an integrative pipeline for gene fusion detection from RNA-seq data in acute pediatric leukemia.Frontiers in molecular biosciences · 2023Article
- Novel read-through fusion transcript Bcl2l2-Pabpn1 in glioblastoma cells.Journal of cellular and molecular medicine · 2022Article
- Article
- Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.European journal of endocrinology · 2022Article
- Functional characterization of NPM1-TYK2 fusion oncogene.NPJ precision oncology · 2022Article
- Discovery of clinically relevant fusions in pediatric cancer.BMC genomics · 2021Article
- Advances in targeting 'undruggable' transcription factors with small molecules.Nature reviews. Drug discovery · 2021Review
- Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.NPJ precision oncology · 2021Article
- A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML.Blood · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric cancers differ from adult tumors, especially by their very low mutational rate. Therefore, their etiology could be explained in part by other oncogenic mechanisms such as chromosomal rearrangements, supporting the possible implication of fusion genes in the development of pediatric cancers. Fusion genes result from chromosomal rearrangements leading to the juxtaposition of two genes. Consequently, an abnormal activation of one or both genes is observed. The detection of fusion genes has generated great interest in basic cancer research and in the clinical setting, since these genes can lead to better comprehension of the biological mechanisms of tumorigenesis and they can also be used as therapeutic targets and diagnostic or prognostic biomarkers. In this review, we discuss the molecular mechanisms of fusion genes and their particularities in pediatric cancers, as well as their relevance in murine models and in the clinical setting. We also point out the difficulties encountered in the discovery of fusion genes. Finally, we discuss future perspectives and priorities for finding new innovative therapies in childhood cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.